Home > Quotes > EPRS

EPIRUS Biopharmaceuticals, Inc. Common Stock Quote & Summary Data

Get EPRS Alerts
*Delayed - data as of Apr. 29, 2016  -  Find a broker to begin trading EPRS now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

EPIRUS Biopharmaceuticals, Inc. Common Stock Intraday Chart

Shares Traded

Trading Range

Intraday Last 52 Weeks
High $ 3.08 $ 8.75
Low $ 2.8284 $ 2.10

The current last sale of $2.90 is 38.10% Higher thanthe 52 week low.

P/E Ratio

Company Description (as filed with the SEC)

EPIRUS is building a global biosimilar enterprise to improve patient access to important medicines. The company's strategy for commercial success relies on targeted approaches for diverse global markets. For emerging markets with accessible regulatory frameworks for biosimilars, EPIRUS develops partnerships with local companies to accelerate regulatory approval and commercialize its products. For high-growth global markets where local manufacturing confers strategic and operational advantages, EPIRUS intends to use its SCALE™ platform to deliver an "In Market, For Market™" manufacturing solution with local partners. For large markets with an established biosimilar regulatory framework, such as Europe, EPIRUS plans to commercialize its products using a combination of direct sales and local distributors. EPIRUS' lead product is BOW015, a biosimilar version of Remicade (infliximab), which is used for the treatment of various inflammatory diseases.   ... More ...  

Risk Grade

Where does EPRS fit in the risk graph?

Risk Grade Scale

Nasdaq Official Price

Consensus Recommendation

Research Brokers before you trade

Want to trade FX?